✦ LIBER ✦

600 Pharmacokinetics and Pharmacodynamics of a Selective Oral MEK1/2 Inhibitor, Pimasertib (MSC1936369B/AS703026), in Patients with Advanced Solid Tumors

✍ Scribed by Houédé, N.; Delord, J.P.; Awada, A.; Lebbe, C.; Lesimple, T.; Schellens, J.H.M.; Rottey, S.; Kefford, R.; von Richter, O.; Raymond, E.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

616 Pimasertib (MSC1936369B/AS703026), a

✍ Delord, J.P.; Houédé, N.; Awada, A.; Lebbe, C.; Lesimple, T.; Schellens, J.H.M.; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 60 KB

608 Phase I Dose-escalation Trial of a S

✍ Naing, A.; Mita, M.; Komarnitsky, P.; Milner, A.; von Richter, O.; Ogden, J.; Pi 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 64 KB

374 Clinical, pharmacokinetic (PK) and p

✍ A. Awada; N. Houedé; J.P. Delord; M. Dubuisson; A. Italiano; Y. Bergé; S. Faivre 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 46 KB

604 Safety and Recommended Phase II Dose

✍ Awada, A.; Delord, J.P.; Houédé, N.; Lebbe, C.; Lesimple, T.; Schellens, J.H.M.; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 78 KB

Phase Ib/II, open-label, dose-escalation

✍ Kefford, Richard; Sullivan, Ryan J; Miller, Wilson H; Elez, Elena M; Tan, Daniel 📂 Article 📅 2014 🏛 BioMed Central 🌐 English ⚖ 91 KB

580 First-in-human, Safety, Pharmacokine

✍ Dienstmann, R.; Lassen, U.; Cebon, J.; Desai, J.; Brown, M.P.; Evers, S.; Su, F. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 75 KB